BSE Live
Mar 23, 16:01Prev. Close
6102.25
Open Price
5923.75
Bid Price (Qty.)
6001.00 (1)
Offer Price (Qty.)
6011.85 (1)
NSE Live
Mar 23, 15:59Prev. Close
6100.00
Open Price
6036.50
Bid Price (Qty.)
6013.50 (310)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Divis Laboratories (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 1,813.29 | 1,833.23 | 1,219.36 | 1,388.23 | 1,371.84 | |
| Net CashFlow From Operating Activities | 1,208.47 | 964.06 | 764.72 | 1,149.11 | 1,032.40 | |
| Net Cash Used In Investing Activities | -81.38 | -684.24 | -475.89 | -1,137.41 | -413.43 | |
| Net Cash Used From Financing Activities | -1,091.25 | -245.94 | -314.17 | 3.27 | -624.14 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 35.84 | 33.88 | -25.34 | 14.97 | -5.17 | |
| Cash And Cash Equivalents Begin of Year | -7.96 | -41.84 | -16.50 | -31.47 | 9.06 | |
| Cash And Cash Equivalents End Of Year | 27.88 | -7.96 | -41.84 | -16.50 | 3.89 |
25.02.2026
Divis Labs Consolidated December 2025 Net Sales at Rs 2,604.00 crore, up 12.29% Y-o-Y
25.02.2026
Divis Labs Standalone December 2025 Net Sales at Rs 2,578.00 crore, up 12.23% Y-o-Y
12.02.2026
Accumulate Divis Laboratories; target of Rs 6850: Prabhudas Lilladher
20.11.2025
Accumulate Divis Laboratories; target of Rs 6795: Deven Choksey
25.02.2026
Divis Labs Consolidated December 2025 Net Sales at Rs 2,604.00 crore, up 12.29% Y-o-Y
25.02.2026
Divis Labs Standalone December 2025 Net Sales at Rs 2,578.00 crore, up 12.23% Y-o-Y
14.11.2025
Divis Labs Consolidated September 2025 Net Sales at Rs 2,715.00 crore, up 16.12% Y-o-Y
12.11.2025
Divis Labs Standalone September 2025 Net Sales at Rs 2,660.00 crore, up 15.55% Y-o-Y
24.05.2024
Divi's Labs Q4 preview: Revenue, net profit to grow on normalised base, better product mix
04.11.2023
Divi's Labs Q2 Preview: Earnings likely to improve sequentially on better margins, product mix
14.08.2023
Divi's Labs Q1 Preview: Base effect to pressure earnings, brokerages predict sequential recovery
19.05.2023
Divi's Labs Preview: Unfavourable base, elevated input costs to turn Q4 a sour pill
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth